AbbVie Inc. Stock Underperforms Monday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.AbbVie Inc. (ABBV) shares fell 2.42% to $254.76 on Monday, underperforming the broader market as the S&P 500 and Dow Jones rose. The stock closed 2.63% below its 52-week high of $261.64. Trading volume was below the 50-day average. Compared to competitors, AbbVie's decline was mixed against Johnson & Johnson, Pfizer, and Amgen, which also saw declines.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of AbbVie Inc. (ABBV) slid 2.42% to $254.76 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.72% to 7,537.43 and the Dow Jones Industrial Average rising 0.29% to 53,055.91.
AbbVie Inc. closed 2.63% below its 52-week high of $261.64, which the company achieved on July 2nd.
The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson & Johnson (JNJ) fell 1.41% to $259.33, Pfizer Inc. (PFE) fell 2.47% to $23.72, and Amgen Inc. (AMGN) fell 2.06% to $366.44.
Trading volume (6.9 M) remained 419,543 below its 50-day average volume of 7.3 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 6, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-06-26 1631ET